Clinical Trial Update: Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial update investigating maintenance therapy with orelabrutinib after autologous stem cell transplant in primary central nervous system lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Ruijin Hospital | Conditions: Primary Central Nervous System Lymphoma | Phase 3 | Status: UNKNOWN